DarioHealth (Nasdaq:DRIO) announced today that it agreed with Dexcom (Nasdaq:DXCM) to integrate continuous glucose monitoring into its digital health platform.
Dexcom CGM uses small, wearable sensors to continuously measure and send glucose levels to a receiver or smart device. The company’s latest CGM technology, the Dexcom G7, recently received FDA clearance. The company plans to announce its U.S. launch in a commercial during the Super Bowl on Feb. 12.
The agreement between DarioHealth and Dexcom enables the integration of CGM data into DarioHealth’s chronic condition platform. This allows users of the wearable device to benefit from DarioHealth’s personalized digital therapeutic support.
Get the full story at our sister site, Drug Delivery Business News.